Bilaketaren emaitzak - Petri Bono

Findu emaitzak
  1. 1
    Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

    Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma nork Petri Bono, Juhana Rautiola, Tapio Utriainen, Heikki Joensuu

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Layilin, a Novel Integral Membrane Protein, Is a Hyaluronan Receptor

    Layilin, a Novel Integral Membrane Protein, Is a Hyaluronan Receptor nork Petri Bono, Kristofer Rubin, Jonathan M.G. Higgins, Richard O. Hynes

    Argitaratua 2001
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy

    Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy nork Pia Österlund, Leena‐Maija Soveri, Helena Isoniemi, Tuija Poussa, Tuomo Alanko, Petri Bono

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Cloning of Vascular Adhesion Protein 1 Reveals a Novel Multifunctional Adhesion Molecule

    Cloning of Vascular Adhesion Protein 1 Reveals a Novel Multifunctional Adhesion Molecule nork David J. Smith, Marko Salmi, Petri Bono, Jukka Hellman, Taina Leu, Sirpa Jalkanen

    Argitaratua 1998
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    High LYVE-1–Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer

    High LYVE-1–Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer nork Petri Bono, Veli-Matti Wasenius, Päivi Heikkilä, Johan Lundin, David G. Jackson, Heikki Joensuu

    Argitaratua 2004
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma

    Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma nork Petri Bono, Hedvig Elfving, Tapio Utriainen, Pia Österlund, Tiina Saarto, Tuomo Alanko, Heikki Joensuu

    Argitaratua 2009
    Testu osoa Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy

    Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy nork Leena‐Maija Soveri, Annamarja Lamminmäki, Ulrika A. Hänninen, Markku Karhunen, Petri Bono, Pia Österlund

    Argitaratua 2019
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73.

    CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. nork Laura Airas, J. Hellman, Marko Salmi, Petri Bono, Tarja Puurunen, David J. Smith, Sirpa Jalkanen

    Argitaratua 1995
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours nork Malaka Ameratunga, Irene Braña, Petri Bono, Sophie Postel‐Vinay, Ruth Plummer, John Aspegrén, Timo Korjamo, Amir Snapir, Johann S. de Bono

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Cytoplasmic HuR Expression Is a Prognostic Factor in Invasive Ductal Breast Carcinoma

    Cytoplasmic HuR Expression Is a Prognostic Factor in Invasive Ductal Breast Carcinoma nork Mira Heinonen, Petri Bono, Kirsi Narko, Sung-Hee Chang, Johan Lundin, Heikki Joensuu, Henry Furneaux, Timothy Hla, Caj Haglund, Ari Ristimäki

    Argitaratua 2005
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    VEGFR-3 Expression Is Restricted to Blood and Lymphatic Vessels in Solid Tumors

    VEGFR-3 Expression Is Restricted to Blood and Lymphatic Vessels in Solid Tumors nork Tatiana V. Petrova, Petri Bono, Wolfgang Holnthoner, Jessica Chesnes, Bronislaw Pytowski, Harri Sihto, Pirjo Laakkonen, Päivi Heikkilä, Heikki Joensuu, Kari Alitalo

    Argitaratua 2008
    Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Absence of the Endothelial Oxidase AOC3 Leads to Abnormal Leukocyte Traffic In Vivo

    Absence of the Endothelial Oxidase AOC3 Leads to Abnormal Leukocyte Traffic In Vivo nork Craig Stolen, Fumiko Marttila‐Ichihara, Kaisa Koskinen, Gennady G. Yegutkin, Raisa Turja, Petri Bono, Mikael Skurnik, Arno Hänninen, Sirpa Jalkanen, Marko Salmi

    Argitaratua 2005
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study

    Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study nork Christophe Massard, Heidi Penttinen, Egils Vjaters, Petri Bono, V. Lietuvietis, Teuvo L.J. Tammela, Annamari Vuorela, Pirjo Nykänen, Pasi Pohjanjousi, Amir Snapir, Karim Fizazi

    Argitaratua 2015
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Expression and prognostic value of transcription factor PROX1 in colorectal cancer

    Expression and prognostic value of transcription factor PROX1 in colorectal cancer nork Maria S. Skog, Petri Bono, Mikael Lundin, Johan Lundin, Johanna Louhimo, Nina Linder, Tatiana V. Petrova, Leif C. Andersson, Heikki Joensuu, Kari Alitalo, Caj Haglund

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer

    Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer nork Sherene Loi, Stefan Michiels, Diether Lambrechts, Debora Fumagalli, Bart Claes, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono, Vesa Kataja, Martine Piccart, Heikki Joensuu, Christos Sotiriou

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

    Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study nork Heikki Joensuu, Filippo de Braud, G Grignagni, Tommaso De Pas, Giosafat Spitalieri, Paola Coco, Carlo Spreafico, Sabrina Boselli, Francesca Toffalorio, Petri Bono, T. Jalava, Christian Kappeler, Massimo Aglietta, Dirk Laurent, Paolo G. Casali

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

    Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial nork Sherene Loi, Stefan Michiels, Roberto Salgado, Nicolas Sirtaine, Vinu José, Debora Fumagalli, Pirkko Kellokumpu‐Lehtinen, Petri Bono, Vesa Kataja, Christine Desmedt, Martine Piccart, Sibylle Loibl, Carsten Denkert, Mark J. Smyth, Heikki Joensuu, Christos Sotiriou

    Argitaratua 2014
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

    Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 d... nork Karim Fizazi, Christophe Massard, Petri Bono, Robert H. Jones, Vesa Kataja, Nicholas D. James, Jorge A. García, Andrew Protheroe, Teuvo L.J. Tammela, Tony Elliott, Leena Mattila, John Aspegrén, Annamari Vuorela, Peter Langmuir, Mika Mustonen

    Argitaratua 2014
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

    Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study nork Bernard Escudier, Camillo Porta, Petri Bono, Thomas Powles, Tim Eisen, Cora N. Sternberg, Jürgen E. Gschwend, Ugo De Giorgi, Omi Parikh, Robert D. Hawkins, Emmanuel Sevin, Sylvie Négrier, Sadya Khan, Jose Diaz, Suman Redhu, Faisal Mehmud, David Cella

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer

    Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer nork Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen, Arja Jukkola‐Vuorinen, Minna Tanner, R. Kokko, Johan Ahlgren, Päivi Auvinen, Outi Lahdenperä, Sanna Kosonen, Kenneth Villman, Paul Nyandoto, Greger Nilsson, Paula Poikonen‐Saksela, Vesa Kataja, Jouni Junnila, Petri Bono, Henrik Lindman

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: